objeCtives: General practitioners (GPs) play an essential role in France in the prescription and administration of vaccines. Understanding factors that influence GPs' opinions regarding vaccination would help improve vaccination rate in the general population. The study objectives were to understand and describe GPs' attitudes, beliefs and behaviours regarding vaccination, to develop a self-report tool enabling characterisation of GPs, to assess the prevalence and determinants of vaccination behaviours and to identify the modifiable barriers regarding vaccination. Methods: Focus groups with French GPs (n= 36) were conducted following a semi-structured interview guide. Main themes of the guide were identified through a literature review. Qualitative analysis enabled development of a conceptual framework based on the theory of planned behaviour (TPB). Items were then generated based on GPs' quotations. Cognitive debriefing interviews with GPs (n= 10) were conducted to assess understanding, acceptability and content validity of the tool. Research methods and results were approved by a committee involving GPs, vaccination and tool development experts. Results: Focus groups revealed that GPs' attitudes, beliefs and behaviours regarding vaccination varied depending on target disease and population. GPs were influenced by factors classified in 6 themes: vaccine characteristics, disease characteristics, practical aspects, expected benefits, personal background and relationship with patients. These qualitative findings supported item generation of the tool to capture 39 detailed concepts. The tool was developed to be generic for any disease that could be prevented by vaccination. Comprehension testing to confirm the relevance and understanding of the tool is underway. ConClusions: The tool was developed following rigorous methodology based on documented qualitative research. The TPB seems appropriate for organising qualitative research findings. Characterisation of GPs based on their attitudes, beliefs and behaviours regarding vaccination is expected to predict their intention to vaccinate and thus enable development of efficient programs promoting vaccination. The next step is to perform psychometric validation.
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A cAse study of fdA PrActIces ANd Its INflueNce oN reGulAtory ANd reImBursemeNt decIsIoNs for dAruNAvIr Rubinstein J. , Rubinstein E. , Jaksa A. , Jao R. , Satyarthi H. , Liden D. Context Matters, Inc., New York, NY, USA objeCtives: It is assumed that agencies influence one another but little has been written on the extent of this influence. This analysis aims to explore how regulatory decisions affect reimbursement decisions within one HIV drug, darunavir. Methods: Documents from the FDA, European Public Assessment Report (EPAR), Health Canada, and the Australian Register of Therapeutic Goods together with the reimbursement decisions from France, Scotland, Canada and Australia were analyzed. The clinical trials found in these documents were compared. Results: The FDA approved darunavir ethanolate on June 23, 2006 based on the POWER 1, 2 and 3 clinical trials. After approval, the FDA also required further reports (to be completed by December 31, 2007) on two Phase III studies, ARTEMIS and TITAN. Health Canada approved darunavir on July 28, 2006 and used the POWER studies along with the ARTEMIS and TITAN studies in its decision. The EMA approved darunavir on December 2, 2007 but gave conditional authorization a year earlier. EPAR also used the TITAN and POWER studies to make its decision. The French reimbursement agency used the ARTEMIS and TITAN studies in two recommendations. Scotland and Canada cited the ARTEMIS study in their recommendations. Australia used the POWER and TITAN studies in two recommendations and the ARTEMIS study in its one negative recommendation, citing an inappropriate comparator for the population under review. ConClusions: Studies that required further review by the FDA after approval were key in determining regulatory decisions by Health Canada, EMA and Australia. The reimbursement decisions of France, Scotland, Canada and Australia also relied on these commissioned studies.
PIN140 clINIcAl GuIdelINes evIdeNce As A crIterIoN for chANGes IN the leGIslAtIoN comBAtING tuBerculosIs
Stepanenko A, Lishchyshyna O. , Melnyk Y. The State Expert Center of the Ministry of Health of Ukraine, Kyiv, Ukraine chronic (e.g., diabetes, hypercholesterolemia, schizophrenia) rather than life-threatening and that treatments, while costly, lead to significant savings in medical benefits and ultimately leave medication decisions to specialists. Payers are cautiously examining potential savings and were willing to institute modest management for generics (tier 1) while keeping branded FDCs on preferred tier 2 (branded preferred copay). Payers were unwilling to institute, high cost-sharing co-insurance, prior authorizations, or require failure for members to access branded HIV medications presently or in the near future. ConClusions: Payers recognize the complexity of treating HIV, the role of adherence, the high cost of failure and the public health component of preventing resistance. We found payers to cautiously look at potential cost savings in medication management until all FDC components become generic. We found no widespread desire to drive generic adoption in HIV treatment, and little interest in the "de-simplification" of currently available FDCs. (TB) is a known factor that would promote drug resistance, thus increasing the overall cost of TB management. The study objectives are to identify the general characteristics of defaulting patients and to estimate the cost impact on health authorities as compared to nondefaulters. Methods: A retrospective case-control study was carried out in public treatment centres in Selangor, Malaysia. Defaulter is defined as TB patient who has interrupted treatment for two consecutive months or more and did not complete their treatment. All subjects were selected from 2011 TB District Registry database. Patients' medical case notes and baseline characteristics were reviewed and analysed. The direct costs of TB management were estimated from public health cost references. The study was performed from a government's perspective. Results: A total of 176 defaulters and 204 non-defaulters were studied. Foreign-born patients showed a higher risk (OR= 5.929; p < 0.01) of defaulting treatment. Unemployed patients were also more likely to default treatment (OR= 1.521 p> 0.05). Defaulters were more likely to default treatment during intensive phase as compared to maintenance phase (68.1% vs. 31.9%; p< 0.05). No other significant findings were observed between the two groups including age, ethnicity, severity of x-ray changes, type of TB and overall medical risk factors. Mean cost of the non-defaulter group is higher than the defaulter group due to a complete treatment (RM 1,259.62 vs. RM 575.58; p< 0.05). No significant treatment cost difference was observed in foreign-born defaulters as compared to local Malaysians (mean: RM 576.43 vs. RM 573.78; p> 0.05). ConClusions: Data from this study suggest TB treatment should be completed to avoid a potential huge waste of resources. More attentions are required for foreign-born defaulters due to overall consequence in public health and management cost. Additional costs would be required if susceptible TB strains of the defaulters turned into more virulent strains. Muenster, Muenster, Germany, 3 GlaxoSmithKline GmbH & Co, Munich, Germany, 4 IMS Health, Alexandria, VA, USA objeCtives: To describe the burden of influenza for children and adults diagnosed with seasonal influenza in Germany. Methods: The study was based on a retrospective database analysis, using a longitudinal electronic medical records database (IMS® Disease Analyzer). Patients with influenza episodes (ICD-10 diagnosis J09-11) being observable 12 months before index date and 1 month afterwards were included. The selection window was May 2010 to April 2012 to cover two influenza seasons. Results: A total of 23,068 influenza episodes (19,446 patients) managed by primary care practitioners (PCP) and 7,295 episodes (5,988 patients) managed by pediatricians were eligible. Mean age of patients was 43±20 years in the PCP panel and 7±4 years in the pediatrician panel. The presence of clinical risk factors was documented for 40% of episodes in adults and 31% of episodes in children. The most common risk factors were cardiovascular diseases in adults (28%) and chronic respiratory diseases in children (26%). The presence of risk factors correlated with the number of episodes/patient. Influenza episodes were frequently accompanied by complications (adults: 38%; children: 57%). Bronchitis (adults: 16%, children: 20%) and acute upper respiratory infections (adults: 15%, children: 21%) accounted for the most frequent complications. Mean number of physician visits was 1.2± 0.5 in adults and 1.5±0.8 in children. Nevertheless one in three children (34%) had more than one visit/episode due to complications. About 60% of episodes (adults: 60%; children: 64%) with at least one complication were reported in patients without risk factors. About 50% of patients received drug prescriptions related either to influenza diagnosis or complications. ConClusions: This study demonstrates that in Germany seasonal influenza is associated with a substantial disease burden and considerable resource utilization, which can be preventable by vaccination. The findings may suggest the modification of the current vaccination recommendation for at risk populations.
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